The excellent efficacy of gemtuzumab ozogamicin in acute promyelocytic leukemia (Breccia and Lo‐Coco, 2011) which is CD33‐dense suggests that the therapeutic window is likely to be widest when AML subtypes are chosen with high receptor levels. The gene discussed is CD33; the disease is acute myeloid leukemia.